Effect of Pretreatment with a Small Dose of Esketamine on Myoclonus Induced by Etomidate: A Randomized Controlled Trial
Liangliang Gao,Xinyu Lu,Aiping Tan,Jiaying Liufu,Yidan Xu,Lei Wei
DOI: https://doi.org/10.2147/dddt.s495130
IF: 4.3188
2024-12-08
Drug Design Development and Therapy
Abstract:Liangliang Gao, 1, 2 Xinyu Lu, 1 Aiping Tan, 3 Jiaying Liufu, 3 Yidan Xu, 1 Lei Wei 3 1 Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, People's Republic of China; 2 The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China; 3 Department of Anesthesiology, Suzhou Hospital Affiliated to Nanjing Medical University, Suzhou, People's Republic of China Correspondence: Lei Wei, Department of Anesthesiology, Suzhou Hospital Affiliated to Nanjing Medical University, No. 26, Daoqian Street, Suzhou, 215000, People's Republic of China, Email Background: Etomidate has been observed to precipitate myoclonus in patients undergoing induction of general anaesthesia. This study was designed to investigate the effect of pretreatment with a small dose of esketamine on the incidence of myoclonus induced by etomidate. Methods: One hundred adult patients, who were scheduled to undergo selective operations with general anesthesia, were randomly divided into two groups, with one group receiving esketamine (Group E) and the other receiving normal saline (Group C). The group receiving esketamine (Group E) was administered an injection of 0.15 mg/kg of esketamine, while the control group (Group C) was given an equivalent volume of normal saline two minutes before the administration of 0.3 mg/kg of etomidate. The primary objective was to determine the incidence of etomidate-induced myoclonus. Secondary endpoints included the severity of etomidate-induced myoclonus and changes in haemodynamic variables at various time intervals. Additionally, the incidence of adverse effects such as dizziness, bradycardia, hypotension and hallucination were recorded from the administration of esketamine or normal saline to the injection of etomidate. Results: The incidence of myoclonus was significantly lower in Group E (20%) than in Group C (62%). Compared with the control group, the esketamine group also experienced a reduction in the moderate and severe of myoclonus. However, there was no statistically significant difference between the two groups for mild etomidate-induced myoclonus. The haemodynamic data (mean arterial pressure and heart rate) showed no statistically significant differences between two groups at the three time points. The incidence of dizziness, bradycardia, hypotension and hallucination was similar in both groups. Conclusion: Pretreatment with 0.15 mg/kg esketamine prior to anaesthesia induction with etomidate was observed to markedly reduce the incidence and severity of myoclonus, while having no effect on mild etomidate-induced myoclonus and maintaining a stable haemodynamic status. Keywords: esketamine, etomidate, myoclonus, pretreatment Etomidate is recommended as a anaesthetic agent for patients with compromised cardiovascular function, due to its minimal cardiopulmonary side effects and stable cardiovascular profile. 1 However, the administration of etomidate may be associated with certain unfavourable effects such as pain on injection and myoclonus. Pain on injection has been alleviated by the implementation of a lipid formulation of etomidate. 2 However, etomidate-induced myoclonus remains a significant clinical concern, with an incidence rate of 50% to 80% in patients who have not received premedication. 3,4 Myoclonic movements have the potential to cause patient discomfort, present a challenge for those with partial cardiovascular reserves, and increase the risk of aspiration for those with a full stomach. Moreover, myoclonus may result in elevated intraocular pressure, which can present complications in patients undergoing open-eye surgery. 5,6 Although the underlying mechanisms of myoclonus are not fully comprehended, various interventions have been adopted to prevent the emergence of myoclonus during the induction phase of anesthesia, including lidocaine, 6 midazolam, 7 opioids, 8,9 dexmedetomidine, 10 or ketamine 11 as well as with non-pharmacological approaches like transcutaneous acupoint electrical stimulation 12 and extend injection time. 1 The implementation of these interventions extensively in clinical practice is currently not feasible due to the various adverse effects they can cause, which include onset time, hypotension, heart rhythm, cough, respiratory depression and chest wall rigidity. Esketamine, an inhibitor of the N-methyl-D-aspartate (NMDA) receptor, has been demonstrated to confer beneficial effects during surgical procedures, including sedation, anti-anxiety properties and analgesia. Furthermore, it has been observed to have a lower -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal